DMPK CRISPR/Cas13-gene therapy (HuidaGene Therapeutics)

N/A

Report date: 2025/01/26 19:12:53

Base Information

Drug NameDMPK CRISPR/Cas13-gene therapy (HuidaGene Therapeutics)
Drug Alias NameRNA-based DMPK gene therapy (HuidaGene Therapeutics)myotonic dystrophy CRISPR-Cas13 gene therapy (HuidaGene Therapeutics)
ClassificationBiologics
Mechanisms of ActionMyotonin-protein kinase inhibitors
TargetsMyotonin-protein kinase
Therapy Area/IndicationsMyotonic Dystrophy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHuidaGene Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHuidaGene Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsMyotonic Dystrophy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A